Register for email alerts and news feeds:
This journal | BMJ Group
rss
Drug and Therapeutics Bulletin 2007;45:5-8; doi:10.1136/dtb.2007.4515
Copyright © 2007 by the BMJ Publishing Group Ltd.

{blacktriangledown}Exubera: inhaled insulin for diabetes

Relevant BNF section: 6.1.1.1

Over 2 million people in the UK have diabetes mellitus, of whom around 20% have type 1 and 80% type 2 disease.1 A key aim of treatment is to optimise glycaemic control to minimise symptoms, prevent complications and extend survival. To these ends, subcutaneous insulin is used to manage all patients with type 1 diabetes and some patients with type 2 diabetes. Another potential route of administering insulin is by inhalation. {blacktriangledown}Exubera (Pfizer), the first licensed inhaled insulin in the UK, is promoted as "the new look of insulin" and as maintaining "long-term glycaemic control". What does it offer in the management of patients with diabetes?


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?